Day: November 14, 2021

89bio Presents New Data from Phase 1b/2a NASH Study Showing BIO89-100 Reduces Spleen Volume 

89bio Presents New Data from Phase 1b/2a NASH Study Showing BIO89-100 Reduces Spleen Volume 

New sub-analysis presented at The Liver Meeting® 2021 shows treatment with BIO89-100 reduced spleen volume by an average of 11.8% in NASH patients Oral presentation was highlighted by the AASLD Scientific Program Committee as a key presentation in The Liver Meeting® 2021 SAN FRANCISCO, Nov. 14, 2021 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the presentation of new data from a post-hoc analysis of the Phase 1b/2a proof-of-concept study evaluating BIO89-100 in patients with nonalcoholic steatohepatitis (NASH) at The Liver Meeting® 2021 of the American Association for the Study of Liver Diseases (AASLD). The sub-analysis, which assessed the...

Continue reading

NOBLE Study Brings Advanced Prostate Imaging to Rural Australia – First Patient Dosed

NOBLE Study Brings Advanced Prostate Imaging to Rural Australia – First Patient Dosed

MELBOURNE, Australia, Nov. 15, 2021 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first Australian patient has been dosed in the international NOBLE Registry, a global study that aims to improve access for men to state-of-the-art prostate cancer imaging tools. The NOBLE Registry is co-supported by Telix and Brussels-based Oncidium Foundation. The NOBLE (Nobody Left Behind) Registry is collecting clinical data to inform the development of TLX599-CDx (99mTc-iPSMA), an investigational prostate cancer imaging agent that targets PSMA (prostate specific membrane antigen) using single photon emission computed tomography (SPECT). The Australian arm of the NOBLE study is being led by PhD researcher Peter Tually at TeleMed in collaboration with Clinical Professor Nat Lenzo, and Professor...

Continue reading

Production report for October 2021

Production report for October 2021

Oslo, 14 November 2021 Below please find average gross operated production in October 2021 and corresponding numbers for September 2021. IOX operated         October 2021 September 2021   Boepd(1) Bopd (2) Boepd(1) Bopd (2) Colombia 782 556 747 507 Argentina (3) 2,114 382 2,247 431 (1)   Barrels of oil equivalents per day(2)   Barrels of oil per day(3)   Operated by Selva Maria Oil on behalf of IOX until local authorities approve operator’s licence. Comments In October, average daily production was 2,896 barrels of oil equivalents per day (boepd), compared to 2,994 boepd in September for Argentina and Colombia combined. The slight decrease in production is mainly due to certain temporary operational issues that are further explained below. In Argentina, a combination of operational commercial issues in the Campo Molino field...

Continue reading

Lexicon’s Sotagliflozin Demonstrates Benefits in Heart Failure and Blood Glucose Control Across the Full Range of Kidney Function in New Analysis of Clinical Data

Lexicon’s Sotagliflozin Demonstrates Benefits in Heart Failure and Blood Glucose Control Across the Full Range of Kidney Function in New Analysis of Clinical Data

Post hoc analysis of pooled clinical data from the SOLOIST and SCORED trials supporting benefit of sotagliflozin presented at the virtual American Heart Association Scientific Sessions 2021, including: Sotaglifozin significantly reduced total cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure across the full range of kidney function studied. Sotaglifozin also significantly reduced hemoglobin A1c, a goal of diabetes management, across the full range of kidney function studied, including individuals with moderate-to-severe chronic kidney disease. THE WOODLANDS, Texas, Nov. 14, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis evaluating the clinical benefit of Lexicon’s investigational drug, sotagliflozin, in heart failure and blood...

Continue reading

Frontier Airlines Orders 91 Additional A321neo Aircraft, Tripling Size by 2029

Frontier Airlines Orders 91 Additional A321neo Aircraft, Tripling Size by 2029

Cements Position as America’s Greenest Airline with New A321s Achieving 119MPG Per Seat Frontier Airlines Fleet Plan Chart Nov. 2021 Frontier Airlines Future Fleet Plan Chart as of Nov. 2021 DENVER, Nov. 14, 2021 (GLOBE NEWSWIRE) — Frontier Airlines (NASDAQ: ULCC) today announced a major fleet expansion with an order for 91 additional A321neo aircraft from leading aircraft manufacturer Airbus as part of a larger joint aircraft order across the Indigo Partners portfolio. “These additional A321neo aircraft will enable us to triple the size of the airline by 2029,” said Barry Biffle, president and CEO, Frontier Airlines. “We are already America’s Greenest Airline with an existing fleet that is 43 percent more fuel efficient, on average per seat, than other U.S. carriers. The A321neo is expected to deliver nearly 120...

Continue reading

Philips provides update on earlier announced voluntary CPAP, BiPAP and Mechanical Ventilator recall notification*

Philips provides update on earlier announced voluntary CPAP, BiPAP and Mechanical Ventilator recall notification*

November 14, 2021 Amsterdam, the Netherlands – On June 14, 2021, Royal Philips’ (NYSE: PHG, AEX: PHIA) subsidiary, Philips Respironics, initiated a voluntary recall notification* for certain sleep and respiratory care products to address identified potential health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam in these devices. Following the substantial ramp-up of its production, service, and repair capacity, the repair and replacement program in the US and several other markets is under way. As expected, the US Food and Drug Administration (FDA) recently conducted an inspection of a Philips Respironics manufacturing facility in connection with the recall. On November 12, 2021, the FDA published a list of the observations it provided to Philips Respironics. In accordance with normal practice, Philips Respironics...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.